← Back to Search

Vitamin D Supplement

Vitamin D Supplementation for Premature Birth

N/A
Recruiting
Led By Maria del Mar Romero López, MD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years

Summary

This trial is testing whether giving extremely premature infants a daily dose of vitamin D can improve their lung, bone, immune system, and brain health. The study focuses on babies born very early or with very low birth weight, who are at higher risk for health issues. Vitamin D supplementation has been studied extensively in preterm and low birth weight infants, showing improvements in growth and vitamin D status but mixed results on other health outcomes.

Who is the study for?
The ViDES Trial is for newborns born at less than 28 weeks gestational age or weighing under 1000 grams. It's not for babies with major birth defects, conditions like cystic fibrosis that affect vitamin D absorption, or those deemed too sick by their neonatologist. Babies over 32 weeks GA can't join regardless of weight.
What is being tested?
This trial tests if giving extremely premature infants an extra dose of vitamin D (800 IU/day) helps improve their bone health, lung function, immune system, and brain development compared to usual care during the first month after birth.
What are the potential side effects?
Since this trial involves supplementation in very young infants, side effects are monitored closely but may include typical reactions to supplements such as digestive discomfort or allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Head circumference as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Length as assessed by sex-specific Z-score on the Fenton 2013 Growth Calculator
Neurodevelopmental Disorders
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Usual care plus vitamin D supplementationExperimental Treatment2 Interventions
Infants will receive cholecalciferol 800 IU/day in the first 28 days after birth, given enterally four times per day (0.5mL per dose = 200 IU) until the infant is provided 400 IU/day (when feedings reach about 120 -160 mL/kg/day). At that point the study cholecalciferol will be reduced to 400 IU/day for a total supplementation of 800 IU/day.
Group II: Usual care plus placeboActive Control2 Interventions
Infants will receive placebo (normal saline) in the first 28 days after birth. Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Vitamin D supplementation, typically in the form of cholecalciferol (D3) or ergocalciferol (D2), works by increasing the levels of 25-hydroxyvitamin D [25(OH)D] in the blood. This is crucial for patients with Vitamin D deficiency as it helps in calcium absorption, promoting bone health and reducing the risk of fractures. Additionally, adequate Vitamin D levels support immune function, potentially reducing the risk of infections and inflammation. Emerging evidence also suggests benefits for muscle strength, lung function, and possibly cognitive health. Ensuring sufficient Vitamin D levels is therefore essential for overall health and the prevention of various deficiency-related complications.
Musculoskeletal Pain and Vitamin D Deficiency in Children: A Pilot Follow-up Study of Vitamin D Therapy in Musculoskeletal/Orthopedic Conditions.Vitamin D Supplementation for Childhood Asthma: A Systematic Review and Meta-Analysis.Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
946 Previous Clinical Trials
344,405 Total Patients Enrolled
1 Trials studying Vitamin D Deficiency
50 Patients Enrolled for Vitamin D Deficiency
National Center for Advancing Translational Sciences (NCATS)NIH
362 Previous Clinical Trials
412,304 Total Patients Enrolled
The Gerber FoundationOTHER
43 Previous Clinical Trials
5,959 Total Patients Enrolled

Media Library

800 IU/day vitamin D supplementation with feedings in the first 28 days after birth (Vitamin D Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05459298 — N/A
Vitamin D Deficiency Research Study Groups: Usual care plus placebo, Usual care plus vitamin D supplementation
Vitamin D Deficiency Clinical Trial 2023: 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth Highlights & Side Effects. Trial Name: NCT05459298 — N/A
800 IU/day vitamin D supplementation with feedings in the first 28 days after birth (Vitamin D Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05459298 — N/A
~42 spots leftby Aug 2025